CD8B and lymphoma: Starting from doses of 0.125 μg/ml, SEL1L3-ETA constructs mediate dose-dependent and specific lysis to lymphoma cells (TMD8 and Oci-Ly3) only after induction of expression of SEL1L3-reactive BCRs.